Straits Times Index
3,301.78 +4.23 (+0.13%) S&P 500
5,483.05 +9.82 (+0.18%) Dow
38,881.64 +103.54 (+0.27%) Nasdaq
17,853.89 -3.13 (-0.02%) Bitcoin USD
64,971.59 -423.51 (-0.65%) CMC Crypto 200
1,347.70 -41.70 (-3.00%)
Qiagen N.V. (0RLT.IL)
| Previous close | 43.54 |
| Open | 40.70 |
| Bid | 40.34 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 40.69 - 41.74 |
| 52-week range | 33.78 - 48.18 |
| Volume | |
| Avg. volume | 162,957 |
| Market cap | 10.098B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 30.38 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
Qiagen eyes sales growth of 7% per year until 2028
Diagnostics company Qiagen said on Monday it was targeting 7% currency-adjusted sales growth per year until 2028 on lab testing machines for infections and cancer, as it maps out its post-pandemic strategy. Qiagen has said it will return to growth in adjusted earnings this year, recovering from last year's drop in profit when demand for coronavirus lab tests plunged. "Between life sciences and clinical application, our market is growing between 4% and 6%, so saying 7% means outpacing the market and therefore taking market share," CEO Thierry Bernard told Reuters.
- Zacks
QIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays
QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.
- Zacks
QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform
QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.
